Form 4: Abbott SVP Sells Shares Under 10b5-1 Plan

Abbott Laboratories' Senior Vice President, Eric Shroff, sold 1,586 common shares for approximately $203,000 as part of a pre-arranged trading plan.

Summary

• Eric Shroff, Senior Vice President at Abbott Laboratories (ABT), reported a sale of common shares.
• The transaction involved the disposition of 1,586 common shares without par value.
• The shares were sold on November 25, 2025, at a weighted average price of $128.0218 per share.
• The total value of the shares sold is approximately $203,028.55.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.
• Following this transaction, Eric Shroff directly beneficially owns 30,384 common shares of Abbott Laboratories.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a 10b5-1 plan and does not inherently signal positive or negative sentiment about the company's future prospects. It's a standard part of executive compensation and personal financial planning.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing for a large, established healthcare company. Such sales by executives are common, especially when conducted under a Rule 10b5-1 plan, which allows insiders to set up a pre-planned schedule for selling company stock to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: A minor, routine sale by an executive, unlikely to have a significant impact on share price or company strategy. The sale under a 10b5-1 plan suggests a pre-planned financial move rather than a reaction to new company developments.

Key Dates

Keywords

Abbott Laboratories, ABT, Insider Trading, Form 4, Share Sale, Eric Shroff, 10b5-1 Plan, Senior Vice President